FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380482922> ?p ?o ?g. }

• W4380482922 abstract "Abstract Background Radiotherapy (RT) is the standard of care for most advanced head and neck squamous cell carcinoma (HNSCC) and results in an unfavorable 5-year overall survival of 40%. Despite strong biological rationale, combining RT with immune checkpoint inhibitors does not result in a survival benefit. Our hypothesis is that the combination of these individually effective treatments fails because of radiation-induced immunosuppression and lymphodepletion. By integrating modern radiobiology and innovative radiotherapy concepts, the patient’s immune system could be maximally retained by (1) increasing the dose per fraction so that the total dose and number of fractions can be reduced (HYpofractionation), (2) redistributing the radiation dose towards a higher peak dose within the tumor center and a lowered elective lymphatic field dose (Dose-redistribution), and (3) using RAdiotherapy with protons instead of photons (HYDRA). Methods The primary aim of this multicenter study is to determine the safety of HYDRA proton- and photon radiotherapy by conducting two parallel phase I trials. Both HYDRA arms are randomized with the standard of care for longitudinal immune profiling. There will be a specific focus on actionable immune targets and their temporal patterns that can be tested in future hypofractionated immunoradiotherapy trials. The HYDRA dose prescriptions (in 20 fractions) are 40 Gy elective dose and 55 Gy simultaneous integrated boost on the clinical target volume with a 59 Gy focal boost on the tumor center. A total of 100 patients (25 per treatment group) will be recruited, and the final analysis will be performed one year after the last patient has been included. Discussion In the context of HNSCC, hypofractionation has historically only been reserved for small tumors out of fear for late normal tissue toxicity. To date, hypofractionated radiotherapy may also be safe for larger tumors, as both the radiation dose and volume can be reduced by the combination of advanced imaging for better target definition, novel accelerated repopulation models and high-precision radiation treatment planning and dose delivery. HYDRA’s expected immune-sparing effect may lead to improved outcomes by allowing for future effective combination treatment with immunotherapy. Trial registration The trial is registered at ClinicalTrials.gov; NCT05364411 (registered on May 6th, 2022)." @default.
• W4380482922 created "2023-06-14" @default.
• W4380482922 creator A5005390932 @default.
• W4380482922 creator A5016295167 @default.
• W4380482922 creator A5023906981 @default.
• W4380482922 creator A5033758292 @default.
• W4380482922 creator A5043656051 @default.
• W4380482922 creator A5046941180 @default.
• W4380482922 creator A5061905561 @default.
• W4380482922 creator A5065479377 @default.
• W4380482922 creator A5067583848 @default.
• W4380482922 creator A5070419318 @default.
• W4380482922 creator A5071697710 @default.
• W4380482922 date "2023-06-13" @default.
• W4380482922 modified "2023-10-18" @default.
• W4380482922 title "HYpofractionated, dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase I HYDRA trial" @default.
• W4380482922 cites W2054980631 @default.
• W4380482922 cites W2089257078 @default.
• W4380482922 cites W2115499099 @default.
• W4380482922 cites W2123894372 @default.
• W4380482922 cites W2140753782 @default.
• W4380482922 cites W2148754315 @default.
• W4380482922 cites W2159861935 @default.
• W4380482922 cites W2194646862 @default.
• W4380482922 cites W2512792914 @default.
• W4380482922 cites W2529484692 @default.
• W4380482922 cites W2549524990 @default.
• W4380482922 cites W2567712538 @default.
• W4380482922 cites W2624275086 @default.
• W4380482922 cites W2740752435 @default.
• W4380482922 cites W2788295467 @default.
• W4380482922 cites W2789400833 @default.
• W4380482922 cites W2790452532 @default.
• W4380482922 cites W2802821733 @default.
• W4380482922 cites W2808607186 @default.
• W4380482922 cites W2897350221 @default.
• W4380482922 cites W2901263658 @default.
• W4380482922 cites W2911690798 @default.
• W4380482922 cites W2913777136 @default.
• W4380482922 cites W2944989507 @default.
• W4380482922 cites W2949162809 @default.
• W4380482922 cites W2971981779 @default.
• W4380482922 cites W2986633517 @default.
• W4380482922 cites W3048900150 @default.
• W4380482922 cites W3094359652 @default.
• W4380482922 cites W3094884516 @default.
• W4380482922 cites W3110935156 @default.
• W4380482922 cites W3111160020 @default.
• W4380482922 cites W3125222626 @default.
• W4380482922 cites W3133129681 @default.
• W4380482922 cites W3147500389 @default.
• W4380482922 cites W3176206338 @default.
• W4380482922 cites W3176964818 @default.
• W4380482922 cites W3185501456 @default.
• W4380482922 doi "https://doi.org/10.1186/s12885-023-11031-w" @default.
• W4380482922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37312053" @default.
• W4380482922 hasPublicationYear "2023" @default.
• W4380482922 type Work @default.
• W4380482922 citedByCount "0" @default.
• W4380482922 crossrefType "journal-article" @default.
• W4380482922 hasAuthorship W4380482922A5005390932 @default.
• W4380482922 hasAuthorship W4380482922A5016295167 @default.
• W4380482922 hasAuthorship W4380482922A5023906981 @default.
• W4380482922 hasAuthorship W4380482922A5033758292 @default.
• W4380482922 hasAuthorship W4380482922A5043656051 @default.
• W4380482922 hasAuthorship W4380482922A5046941180 @default.
• W4380482922 hasAuthorship W4380482922A5061905561 @default.
• W4380482922 hasAuthorship W4380482922A5065479377 @default.
• W4380482922 hasAuthorship W4380482922A5067583848 @default.
• W4380482922 hasAuthorship W4380482922A5070419318 @default.
• W4380482922 hasAuthorship W4380482922A5071697710 @default.
• W4380482922 hasBestOaLocation W43804829221 @default.
• W4380482922 hasConcept C126322002 @default.
• W4380482922 hasConcept C143998085 @default.
• W4380482922 hasConcept C2776530083 @default.
• W4380482922 hasConcept C2776833033 @default.
• W4380482922 hasConcept C2780252810 @default.
• W4380482922 hasConcept C2989005 @default.
• W4380482922 hasConcept C509974204 @default.
• W4380482922 hasConcept C71924100 @default.
• W4380482922 hasConceptScore W4380482922C126322002 @default.
• W4380482922 hasConceptScore W4380482922C143998085 @default.
• W4380482922 hasConceptScore W4380482922C2776530083 @default.
• W4380482922 hasConceptScore W4380482922C2776833033 @default.
• W4380482922 hasConceptScore W4380482922C2780252810 @default.
• W4380482922 hasConceptScore W4380482922C2989005 @default.
• W4380482922 hasConceptScore W4380482922C509974204 @default.
• W4380482922 hasConceptScore W4380482922C71924100 @default.
• W4380482922 hasIssue "1" @default.
• W4380482922 hasLocation W43804829221 @default.
• W4380482922 hasLocation W43804829222 @default.
• W4380482922 hasLocation W43804829223 @default.
• W4380482922 hasLocation W43804829224 @default.
• W4380482922 hasLocation W43804829225 @default.
• W4380482922 hasLocation W43804829226 @default.
• W4380482922 hasOpenAccess W4380482922 @default.
• W4380482922 hasPrimaryLocation W43804829221 @default.
• W4380482922 hasRelatedWork W1974239774 @default.
• W4380482922 hasRelatedWork W1995788949 @default.
• W4380482922 hasRelatedWork W2086793060 @default.

• next